IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia
IDEAYA Biosciences (NASDAQ: IDYA) has initiated Investigator Sponsored Trial to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.
